Comparison of Response Evaluation Criteria in Solid Tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: A retrospective analysis. Issue 2 (January 2015)

• Record Type: Journal Article
• Authors: Taieb, Sophie; Saada-Bouzid, Esma; Tresch, Emmanuelle; Ryckewaert, Thomas; Bompas, Emmanuelle; Italiano, Antoine; Guillemet, Cécile; Peugniez, Charlotte; Piperno-Neumann, Sophie; Thyss, Antoine; Maynou, Carlos; Clisant, Stéphanie; Penel, Nicolas; French Sarcoma Group
• Is Part Of: European journal of cancer. Volume 51:Issue 2(2015:Jan.)
• Page Start: 202
• Page End: 209
• Publication Date: 2015-01
• Subjects: Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2014.11.008
• Languages: English
• ISSNs: 0959-8049

Abstract

<abstract xml:lang="en" abstract-type="author" id="ab005"> <title id="st080">Abstract</title> <sec> <title id="st085">Background</title> <p id="sp0005">To assess the additional value of density measurement using contrast-enhancement sequences (Choi assessment) in a real-life cohort of adult soft tissue sarcoma patients treated with trabectedin.</p> </sec> <sec> <title id="st090">Methods</title> <p id="sp0010">Eligibility criteria included adults (age ⩾18) treated between 01/2007 and 12/2011, with at least two trabectedin cycles after failure or intolerance to doxorubicin/ifosfamide. Baseline and first computed tomography (CT)-scans were centrally reviewed by an experienced radiologist.</p> </sec> <sec> <title id="st095">Results</title> <p id="sp0015">The retrospective cohort consists of 134 (73 female) patients treated with trabectedin 1.5 mg/m<sup>2</sup> given as a 24-h infusion every 3 weeks. Patients received a median of five trabectedin cycles (range: 2–33) and the main cause of discontinuation was progressive disease (PD) (<italic>n</italic> = 105, 78.4%). Response Evaluation Criteria in Solid Tumours (RECIST) assessment was feasible in 128 (95.5%) patients, with Choi assessment performed in 92 (68.7%) patients, generally due to inadequate sequences or exclusive lung metastases. Concordance between both methods was fair (Kappa = 0.290). We identified five patients with false PD (i.e. PD according to RECIST but stable disease/partial response as per Choi). Univariate analysis did not identify any predictive factors for false PD. Median overall survival (OS) of patients with PD as per RECIST but stable disease/partial response (SD/PR) according to Choi was better than for patients with PD according to both RECIST and Choi (14 months versus 8 months; <italic>p </italic>= 0.052).</p> </sec> <sec> <title id="st100">Conclusions</title> <p id="sp0020">Choi assessment may identify patients with false PD who achieved improved efficacy outcomes, suggesting that trabectedin may delay tumour progression even in the case of non-dimensional response. Dual size and tumour density assessment may be more suitable to evaluate responses to trabectedin in sarcoma patients as well as to improve the decision-making strategies for the continuation of trabectedin therapy.</p> </sec> </abstract>